Stock Track | Globus Medical Plummets 5.37% Despite Q4 Earnings Beat as Analyst Cuts Price Target

Stock Track

Feb 22, 2025

Globus Medical Inc. (GMED) shares plummeted 5.37% in intraday trading on Friday despite the company reporting better-than-expected fourth-quarter earnings and revenue results. The stock's decline can be attributed to an analyst lowering their price target on the medical device maker.

For the fourth quarter of 2024, Globus Medical reported adjusted earnings per share of $0.84, beating the Zacks Consensus Estimate by 10.5%. The company's revenue of $657.3 million also surpassed expectations, rising 6.6% year-over-year. The strong performance was driven by increased sales of spine products and enabling technologies.

However, Wells Fargo analyst Vik Chopra lowered the firm's price target on Globus Medical to $93 from $95, while maintaining an Overweight rating on the stock. The analyst's price target adjustment likely contributed to the sell-off in GMED shares during Friday's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1193195979"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193195979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193195979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-22 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193195979","market":"us","top_or_hot":-1,"title":"Stock Track | Globus Medical Plummets 5.37% Despite Q4 Earnings Beat as Analyst Cuts Price Target","media":"Stock Track","content":"<p>Globus Medical Inc. (GMED) shares plummeted 5.37% in intraday trading on Friday despite the company reporting better-than-expected fourth-quarter earnings and revenue results. The stock's decline can be attributed to an analyst lowering their price target on the medical device maker.</p>\n\n<p>For the fourth quarter of 2024, Globus Medical reported adjusted earnings per share of $0.84, beating the Zacks Consensus Estimate by 10.5%. The company's revenue of $657.3 million also surpassed expectations, rising 6.6% year-over-year. The strong performance was driven by increased sales of spine products and enabling technologies.</p>\n\n<p>However, Wells Fargo analyst Vik Chopra lowered the firm's price target on Globus Medical to $93 from $95, while maintaining an Overweight rating on the stock. The analyst's price target adjustment likely contributed to the sell-off in GMED shares during Friday's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Globus Medical Plummets 5.37% Despite Q4 Earnings Beat as Analyst Cuts Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Globus Medical Plummets 5.37% Despite Q4 Earnings Beat as Analyst Cuts Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-22 01:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Globus Medical Inc. (GMED) shares plummeted 5.37% in intraday trading on Friday despite the company reporting better-than-expected fourth-quarter earnings and revenue results. The stock's decline can be attributed to an analyst lowering their price target on the medical device maker.</p>\n\n<p>For the fourth quarter of 2024, Globus Medical reported adjusted earnings per share of $0.84, beating the Zacks Consensus Estimate by 10.5%. The company's revenue of $657.3 million also surpassed expectations, rising 6.6% year-over-year. The strong performance was driven by increased sales of spine products and enabling technologies.</p>\n\n<p>However, Wells Fargo analyst Vik Chopra lowered the firm's price target on Globus Medical to $93 from $95, while maintaining an Overweight rating on the stock. The analyst's price target adjustment likely contributed to the sell-off in GMED shares during Friday's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMED","symbol_name":"Globus Medical Inc","start_time":0,"source_url":"","article_id":"1193195979","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193195979","pubTimestamp":1740160041,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Globus Medical Inc.  shares plummeted 5.37% in intraday trading on Friday despite the company reporting better-than-expected fourth-quarter earnings and revenue results. The stock's decline can be attributed to an analyst lowering their price target on the medical device maker.For the fourth quarter of 2024, Globus Medical reported adjusted earnings per share of $0.84, beating the Zacks Consensus Estimate by 10.5%. The company's revenue of $657.3 million also surpassed expectations, rising 6.6% ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GMED":"Globus Medical Inc"},"translate_title":"尽管分析师下调目标价，但Globus Medical第四季度盈利超出预期，股价仍暴跌5.37%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1},"content_text":"Globus Medical Inc. (GMED) shares plummeted 5.37% in intraday trading on Friday despite the company reporting better-than-expected fourth-quarter earnings and revenue results. The stock's decline can be attributed to an analyst lowering their price target on the medical device maker.\nFor the fourth quarter of 2024, Globus Medical reported adjusted earnings per share of $0.84, beating the Zacks Consensus Estimate by 10.5%. The company's revenue of $657.3 million also surpassed expectations, rising 6.6% year-over-year. The strong performance was driven by increased sales of spine products and enabling technologies.\nHowever, Wells Fargo analyst Vik Chopra lowered the firm's price target on Globus Medical to $93 from $95, while maintaining an Overweight rating on the stock. The analyst's price target adjustment likely contributed to the sell-off in GMED shares during Friday's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}